<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Abnormal LFTs (structured approach + referral) — DGRefHelp Drafts</title>
  <link rel="stylesheet" href="../assets/site.css" />
</head>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">
        <h1><a href="../index.html">DGRefHelp drafts</a> / Abnormal LFTs</h1>
        <div class="sub">Primary care approach to abnormal liver blood tests: recognise urgent/synthetic failure, take a focused history/exam, interpret the pattern (hepatitic vs cholestatic vs isolated bilirubin), request a standard liver aetiology screen (BSG/BASL 2018), and risk‑stratify NAFLD/ARLD for fibrosis (FIB‑4/NFS → second‑line ELF/FibroScan; NICE NG49 + BSG).</div>
      </div>
      <div class="badges">
        <div class="badge">Mode: quick</div>
        <div class="badge">Last updated: 2026‑02‑11</div>
      </div>
    </div>

    <div class="grid">
      <div class="card">
        <div class="card-hd">
          <div class="tabs" data-tabs>
            <button class="tab" role="tab" data-tab="evidence" aria-selected="true">Evidence</button>
            <button class="tab" role="tab" data-tab="draft" aria-selected="false">DGRefHelp draft</button>
            <button class="tab" role="tab" data-tab="refs" aria-selected="false">References</button>
          </div>
          <div class="copybar">
            <button class="btn" data-copy-target="#draftText">Copy draft</button>
            <button class="btn" data-copy-target="#evidenceText">Copy evidence</button>
          </div>
        </div>

        <div class="card-bd">
          <div class="panel active" role="tabpanel" data-panel="evidence">
            <div id="evidenceText" class="section">
<h3>Evidence summary (triangulated)</h3>

              <div class="callout ok">
                <strong>Key design points (primary care)</strong>
                <ul>
                  <li><strong>Don’t “watch and wait” abnormal LFTs without context:</strong> BSG recommends people with abnormal liver blood tests should be considered for a <strong>liver aetiology screen irrespective of level/duration</strong>; the degree of abnormality does not reliably indicate severity (BSG/BASL 2018).</li>
                  <li><strong>Use a standard liver aetiology screen</strong> to reduce missed chronic liver disease: in adults this includes <strong>abdominal ultrasound</strong>, hepatitis B surface antigen, hepatitis C antibody (PCR if positive), autoimmune markers (AMA/ASMA/ANA) + immunoglobulins, and iron overload tests (ferritin + transferrin saturation) (BSG/BASL 2018).</li>
                  <li><strong>Risk‑stratify NAFLD for fibrosis rather than using “how high the ALT is”:</strong> first‑line non‑invasive fibrosis assessment via <strong>FIB‑4 or NAFLD fibrosis score</strong> (BSG/BASL 2018). NICE NG49 recommends assessing for advanced fibrosis in people with NAFLD and considers the <strong>ELF test</strong>; <strong>ELF ≥10.51</strong> supports advanced fibrosis and warrants specialist referral (NICE NG49).</li>
                  <li><strong>Escalate urgently</strong> when there is <strong>marked derangement</strong>, <strong>synthetic failure</strong> (e.g. raised INR, low albumin) and/or concerning symptoms/signs (BSG/BASL 2018 pathway figure) — exact local routes vary (ED/SDEC/acute med/gastro/hepatology).</li>
                  <li><strong>Alcohol-related liver disease (ARLD):</strong> BSG recommends considering referral to alcohol services for dependency (AUDIT &gt;19) and using fibrosis assessment; referral to secondary care if evidence of advanced disease or FibroScan &gt;16 kPa (if available) (BSG/BASL 2018).</li>
                </ul>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="draft">

            <div class="callout" style="margin-bottom:12px">
              <strong>Copy/paste HTML for Right Decisions accordion sections</strong>
              <div class="small">Per your preference, these snippets contain section content only (no internal headings). Paste each into the matching accordion section.</div>
              <div style="height:10px"></div>
              <div class="copybar" style="justify-content:flex-start">
                <button class="btn" data-copy-target="#htmlBackground">Copy Background HTML</button>
                <button class="btn" data-copy-target="#htmlAssessment">Copy Assessment HTML</button>
                <button class="btn" data-copy-target="#htmlPCM">Copy Primary care mgmt HTML</button>
                <button class="btn" data-copy-target="#htmlRefer">Copy Who to refer HTML</button>
                <button class="btn" data-copy-target="#htmlNotRefer">Copy Who not to refer HTML</button>
                <button class="btn" data-copy-target="#htmlRefs">Copy References HTML</button>
              </div>

              <details style="margin-top:10px">
                <summary class="small" style="cursor:pointer">Show HTML snippets</summary>

                <h4 style="margin:12px 0 6px">Background (HTML)</h4>
                <pre id="htmlBackground">&lt;ul&gt;&lt;li&gt;(Add 1–3 background bullets if desired.)&lt;/li&gt;&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Assessment (primary care) (HTML)</h4>
                <pre id="htmlAssessment">&lt;ul&gt;
                &lt;li&gt;&lt;strong&gt;Acute severe illness&lt;/strong&gt; + abnormal LFTs (sepsis/shock/hypoxia) → manage as acute medical emergency.&lt;/li&gt;
                &lt;li&gt;&lt;strong&gt;Jaundice&lt;/strong&gt; with systemic upset, hypotension, fever/rigors, RUQ pain (possible &lt;strong&gt;cholangitis&lt;/strong&gt;) → urgent hospital assessment.&lt;/li&gt;
                &lt;li&gt;&lt;strong&gt;Suspected acute liver failure / synthetic failure&lt;/strong&gt;: confusion/encephalopathy, &lt;strong&gt;INR raised&lt;/strong&gt;, hypoglycaemia, rapidly rising bilirubin, new ascites, or bleeding/bruising → urgent hospital assessment.&lt;/li&gt;
                &lt;li&gt;&lt;strong&gt;Suspected malignant obstruction&lt;/strong&gt; (painless progressive jaundice, weight loss) → urgent same‑day assessment/urgent imaging route (local).&lt;/li&gt;
                &lt;li&gt;&lt;strong&gt;Marked derangement&lt;/strong&gt; of liver enzymes with symptoms (or very high ALT/AST) → discuss urgently / refer same day (local thresholds; see “Local agreement needed”).&lt;/li&gt;
              &lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Primary care management (HTML)</h4>
                <pre id="htmlPCM">&lt;ul&gt;
                &lt;li&gt;Symptoms: jaundice, pruritus, RUQ pain, fever, weight loss, fatigue, anorexia, pale stools/dark urine.&lt;/li&gt;
                &lt;li&gt;Alcohol: units/week + pattern; use &lt;strong&gt;AUDIT&lt;/strong&gt; where relevant.&lt;/li&gt;
                &lt;li&gt;Metabolic risk: BMI, waist, T2DM, dyslipidaemia, hypertension (NAFLD risk).&lt;/li&gt;
                &lt;li&gt;Drug history: prescribed/OTC/herbal; new drugs in last 3 months; statins, antibiotics, antiepileptics, methotrexate, etc.&lt;/li&gt;
                &lt;li&gt;Viral hepatitis risks: IVDU, transfusion abroad, tattoos/piercings, sexual risk, country of birth/exposure, household contacts.&lt;/li&gt;
                &lt;li&gt;Family history: haemochromatosis, autoimmune disease, liver disease.&lt;/li&gt;
                &lt;li&gt;Exam: jaundice, scratch marks, hepatosplenomegaly, ascites, peripheral oedema, stigmata of chronic liver disease.&lt;/li&gt;
              &lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Who to refer (HTML)</h4>
                <pre id="htmlRefer">&lt;ul&gt;
                &lt;li&gt;&lt;strong&gt;Hepatitic pattern&lt;/strong&gt;: ALT/AST predominant.&lt;/li&gt;
                &lt;li&gt;&lt;strong&gt;Cholestatic pattern&lt;/strong&gt;: ALP (± GGT) predominant; think biliary obstruction, cholangitis, PBC/PSC, drug‑induced cholestasis.&lt;/li&gt;
                &lt;li&gt;&lt;strong&gt;Isolated raised bilirubin&lt;/strong&gt; with normal ALT/ALP: consider Gilbert’s (unconjugated) vs haemolysis; check fractionation, haemolysis screen if indicated.&lt;/li&gt;
                &lt;li&gt;&lt;strong&gt;Low albumin / thrombocytopenia&lt;/strong&gt; (or raised INR) may indicate advanced/chronic liver disease (synthetic/portal hypertension) → lower threshold to refer.&lt;/li&gt;
              &lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Who not to refer (HTML)</h4>
                <pre id="htmlNotRefer">&lt;ul&gt;&lt;li&gt;(If no explicit ‘who not to refer’ applies, omit or keep minimal.)&lt;/li&gt;&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">References (HTML)</h4>
                <pre id="htmlRefs">&lt;ol&gt;&lt;li&gt;(Add references here.)&lt;/li&gt;&lt;/ol&gt;</pre>
              </details>
            </div>

            <div id="draftText" class="section">
<h3>Abnormal LFTs — structured approach + referral triggers (adults)</h3>

              <h4>Immediate red flags (same‑day emergency assessment / ED)</h4>
              <ul>
                <li><strong>Acute severe illness</strong> + abnormal LFTs (sepsis/shock/hypoxia) → manage as acute medical emergency.</li>
                <li><strong>Jaundice</strong> with systemic upset, hypotension, fever/rigors, RUQ pain (possible <strong>cholangitis</strong>) → urgent hospital assessment.</li>
                <li><strong>Suspected acute liver failure / synthetic failure</strong>: confusion/encephalopathy, <strong>INR raised</strong>, hypoglycaemia, rapidly rising bilirubin, new ascites, or bleeding/bruising → urgent hospital assessment.</li>
                <li><strong>Suspected malignant obstruction</strong> (painless progressive jaundice, weight loss) → urgent same‑day assessment/urgent imaging route (local).</li>
                <li><strong>Marked derangement</strong> of liver enzymes with symptoms (or very high ALT/AST) → discuss urgently / refer same day (local thresholds; see “Local agreement needed”).</li>
              </ul>

              <h4>Step 1 — confirm + contextualise (don’t interpret in isolation)</h4>
              <ul>
                <li>Review <strong>previous LFTs</strong> and the clinical context (BSG).</li>
                <li>Repeat if a clear transient cause is likely (e.g. viral illness, recent strenuous exercise affecting AST) but <strong>don’t delay</strong> aetiology screen if persistent/unexplained (BSG).</li>
                <li>Check whether the panel includes: <strong>bilirubin, albumin, ALT, ALP, GGT</strong> + <strong>FBC</strong> (BSG recommendation for initial panel).</li>
              </ul>

              <h4>Step 2 — focused history + examination</h4>
              <ul>
                <li>Symptoms: jaundice, pruritus, RUQ pain, fever, weight loss, fatigue, anorexia, pale stools/dark urine.</li>
                <li>Alcohol: units/week + pattern; use <strong>AUDIT</strong> where relevant.</li>
                <li>Metabolic risk: BMI, waist, T2DM, dyslipidaemia, hypertension (NAFLD risk).</li>
                <li>Drug history: prescribed/OTC/herbal; new drugs in last 3 months; statins, antibiotics, antiepileptics, methotrexate, etc.</li>
                <li>Viral hepatitis risks: IVDU, transfusion abroad, tattoos/piercings, sexual risk, country of birth/exposure, household contacts.</li>
                <li>Family history: haemochromatosis, autoimmune disease, liver disease.</li>
                <li>Exam: jaundice, scratch marks, hepatosplenomegaly, ascites, peripheral oedema, stigmata of chronic liver disease.</li>
              </ul>

              <h4>Step 3 — identify the pattern (helps choose next tests/referral urgency)</h4>
              <ul>
                <li><strong>Hepatitic pattern</strong>: ALT/AST predominant.</li>
                <li><strong>Cholestatic pattern</strong>: ALP (± GGT) predominant; think biliary obstruction, cholangitis, PBC/PSC, drug‑induced cholestasis.</li>
                <li><strong>Isolated raised bilirubin</strong> with normal ALT/ALP: consider Gilbert’s (unconjugated) vs haemolysis; check fractionation, haemolysis screen if indicated.</li>
                <li><strong>Low albumin / thrombocytopenia</strong> (or raised INR) may indicate advanced/chronic liver disease (synthetic/portal hypertension) → lower threshold to refer.</li>
              </ul>

              <h4>Step 4 — minimum investigation set (standard adult liver aetiology screen)</h4>
              <ul>
                <li><strong>Abdominal ultrasound</strong> (assess fatty liver, biliary dilation/obstruction, masses, cirrhotic features) (BSG).</li>
                <li><strong>Viral hepatitis</strong>: HBsAg; HCV antibody (PCR if positive) (BSG).</li>
                <li><strong>Autoimmune</strong>: AMA, ASMA, ANA + serum immunoglobulins (BSG).</li>
                <li><strong>Iron overload</strong>: ferritin + transferrin saturation (BSG).</li>
                <li>Also consider (case‑dependent): HbA1c/lipids, coeliac screen, CK (if isolated AST), TFTs, caeruloplasmin/alpha‑1 antitrypsin (usually specialist‑directed), pregnancy test.</li>
              </ul>

              <h4>Step 5 — NAFLD / metabolic risk pathway (fibrosis risk‑stratify)</h4>
              <ul>
                <li>If fatty liver/metabolic risk factors and no alternative cause: diagnose likely <strong>NAFLD</strong> (after excluding significant alcohol and other causes).</li>
                <li>Risk‑stratify for advanced fibrosis:
                  <ul>
                    <li><strong>First line:</strong> calculate <strong>FIB‑4</strong> (or NAFLD fibrosis score) (BSG).</li>
                    <li><strong>Second line:</strong> if intermediate/high risk → ELF or FibroScan/ARFI (BSG). NICE NG49: consider <strong>ELF</strong>; <strong>ELF ≥10.51</strong> indicates advanced fibrosis → <strong>refer to hepatology</strong>.</li>
                  </ul>
                </li>
                <li>Management basics (primary care): weight loss/lifestyle support; optimise metabolic comorbidities; <strong>statins should generally continue</strong> (NICE NG49; only consider stopping if enzymes double within 3 months of starting).</li>
              </ul>

              <h4>Step 6 — alcohol pathway (ARLD risk)</h4>
              <ul>
                <li>Quantify alcohol use; consider <strong>AUDIT</strong>.</li>
                <li>If alcohol dependency (e.g. <strong>AUDIT &gt;19</strong>) → consider <strong>referral to alcohol services</strong> (BSG).</li>
                <li>Risk‑stratify harmful drinkers for fibrosis if available (FibroScan/ARFI); consider secondary care referral if <strong>advanced disease</strong> suspected or <strong>FibroScan &gt;16 kPa</strong> (BSG).</li>
              </ul>

              <h4>Who to refer / where to send (D&amp;G placeholders)</h4>
              <ul>
                <li><strong>ED / acute medicine (same day)</strong>: red flags above; suspected cholangitis/obstruction with systemic features; suspected synthetic failure/encephalopathy.</li>
                <li><strong>Urgent imaging/surgical/gastro</strong> (local): cholestatic pattern with suspected obstruction; ultrasound showing biliary obstruction or suspicious mass.</li>
                <li><strong>Routine/urgent hepatology/gastro referral</strong>:
                  <ul>
                    <li>Abnormal LFTs with <strong>positive aetiology screen</strong> (viral hepatitis, autoimmune markers + raised Ig, iron overload markers) (BSG).</li>
                    <li><strong>NAFLD with advanced fibrosis</strong> on non‑invasive testing (e.g. ELF ≥10.51) (NICE NG49).</li>
                    <li>Evidence of <strong>advanced liver disease/portal hypertension</strong> (low platelets, low albumin, raised INR, splenomegaly/ascites, nodular liver on USS).</li>
                    <li><strong>Persistent unexplained</strong> abnormal liver blood tests despite negative extended screen and no NAFLD risk factors → refer/discuss for further evaluation (BSG).</li>
                  </ul>
                </li>
              </ul>

              <h4>Referral-letter minimum (suggested)</h4>
              <ul>
                <li>LFT panel values + trend (ALT/AST/ALP/GGT/bilirubin/albumin) + INR if done; FBC incl. platelets.</li>
                <li>Alcohol history (units/week + AUDIT if done); metabolic risk (BMI, T2DM, BP, lipids).</li>
                <li>Full meds list incl. OTC/herbals + recent changes.</li>
                <li>Aetiology screen results (HBsAg, HCV Ab ± PCR, AMA/ASMA/ANA, Ig, ferritin + transferrin saturation) and ultrasound report.</li>
                <li>Fibrosis risk score (FIB‑4/NFS) and any ELF/FibroScan/ARFI result if available.</li>
              </ul>

              <h4>Local agreement needed (add D&amp;G specifics)</h4>
              <ul>
                <li class="check">What counts as <strong>“marked derangement”</strong> in primary care for same‑day referral (e.g. ALT/AST &gt;X, ALP &gt;X, bilirubin &gt;X) and what the default route is (ED vs SDEC vs direct specialty advice).</li>
                <li class="check">How to access/commission <strong>second‑line fibrosis testing</strong> (ELF vs FibroScan/ARFI), including cut‑offs used locally and referral destinations.</li>
                <li class="check">Local pathway for <strong>cholestatic LFTs</strong>: urgent ultrasound timing and which service receives suspected obstruction/cholangitis referrals.</li>
                <li class="check">Whether primary care should request the full <strong>standard liver aetiology screen</strong> up front, or whether some elements are added only after first specialist triage.</li>
                <li class="check">Local policy for <strong>statin</strong> monitoring and thresholds for interruption/rechallenge in people with abnormal baseline LFTs.</li>
              </ul>

              <h4>Related pages</h4>
              <ul>
                <li><a href="./dyspepsia.html">Dyspepsia / reflux symptoms</a> (upper GI cancer triggers)</li>
                <li><a href="./iron-deficiency-anaemia.html">Iron deficiency anaemia</a> (GI workup + FIT routing)</li>
                <li><a href="./pr-bleeding.html">PR bleeding</a> (FIT routing + urgent vs routine)</li>
              </ul>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="refs">
            <div class="section">
              <h3>References (retrieved 2026‑02‑06)</h3>
              <ol>
                <li>RCOG Green‑top Guideline No. 34: Ovarian Cysts in Postmenopausal Women (consensus update Dec 2025; web page last reviewed 05 Dec 2025). <a href="https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/ovarian-cysts-in-postmenopausal-women-green-top-guideline-no-34/">rcog.org.uk</a></li>
                <li>NICE NG12: Suspected cancer — recommendations organised by site of cancer (ovarian cancer section; CA‑125 ≥35 → USS). <a href="https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer">nice.org.uk</a></li>
                <li>Right Decisions (GGC primary care): Ovarian cysts in post-menopausal women (example of local thresholds/RMI approach; not D&amp;G). <a href="https://www.rightdecisions.scot.nhs.uk/ggc-primary-care/womens-health/gynaecology-clinical-guidelines/ovarian-cysts-in-post-menopausal-women-549/">rightdecisions.scot.nhs.uk</a></li>
              </ol>
            </div>
          </div>

        </div>
      </div>

      <div class="footer">
        <a href="../index.html">← Back to topics</a>
      </div>
    </div>
  </div>

  <script src="../assets/site.js"></script>
</body>
</html>
